Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

Identification

Summary

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

Brand Names
Menveo
Generic Name
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
DrugBank Accession Number
DB10061
Background

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria Neisseria meningitidis entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia.1 Several serogroups of N. meningitidis - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.1 Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains serogroup A, C, Y, and W-135 oligosaccharides conjugated individually to Corynebacterium diphtheriae CRM197 protein carrier, resulting in four drug substances contained in each dose of vaccine.2

Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.2

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
Not Available

Pharmacology

Indication

This is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine does not prevent N. meningitidis serogroup B infections.2

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine that works to potentiate immune response against Neisseria meningitidis serogroups A, C, Y, and W-135 in vaccinated individuals.2

Mechanism of action

Neisseria meningitidis is a human-encapsulated Gram-negative diplococcus that is known to cause serious and life-threatening invasive disease. N. meningitidis has several different serogroups that are classified based on the composition of capsular polysaccharide (CPS) polymers. Among the serogroups, serogroups A, B, C, W, Y, and X account for the majority of meningococcal diseases.1

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains bacterial CPS (serogroup A, C, Y, and W-135 oligosaccharides) conjugated to a carrier protein (CRM197), allowing more robust antibody responses compared to plain polysaccharide vaccines.1 Upon administration, this conjugate vaccine promotes the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y, and W-135 in vaccinated individuals.2

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Adalimumab.
AlclometasoneThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Altretamine.
AmcinonideThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Amcinonide.
AmsacrineThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Anakinra.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Menjugate LiquidMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (25 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (10 mcg/0.5mL)SuspensionIntramuscularGlaxosmithkline Inc2015-10-07Not applicableCanada flag
MenveoMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)Powder, for solution; SolutionIntramuscularGlaxosmithkline Inc2010-07-29Not applicableCanada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Neisseria meningitidis

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Daraghma R, Sapra A: Meningococcal Vaccine . [Article]
  2. FDA Approved Drug Products: MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] solution for injection, for intramuscular use [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceMeningitis / Meningococcal Disease / Septicemia1
4CompletedOtherMeningococcal Meningitis1
4CompletedPreventionMeningococcal Disease1
4CompletedPreventionMeningococcal Disease, Invasive1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections / Meningococcal Infections / Pneumococcal Infection1
3Active Not RecruitingPreventionMeningococcal Meningitis1
3CompletedPreventionMeningitis / Septicemia1
3CompletedPreventionMeningococcal Infections3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Powder, for solution; solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at November 30, 2015 21:23 / Updated at November 01, 2022 19:17